TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9917438
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V (250 mg three times a day)
Study: 25304727
Drug: Low-dose interleukin-2
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose interleukin-2 (IL-2) + interferon-α (IFN-α)
Study: 22789797
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (calcium-channel blockers or angiotensin converting enzyme inhibitors)
Study: 15499224
Drug: 3-month formulation
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-month formulation
Study: 15499224
Drug: 28-day formulation
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28-day formulation
Study: 2846480
Drug: Superfractionated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Superfractionated radiation (3 times a day to a total dose of 4760 cGy)
Study: 2846480
Drug: Standard daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard daily treatment (to 4000 cGy)
Study: 2846480
Drug: Standard daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard daily treatment
Study: 4919554
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (Cyclokapron) 1 g four times a day for the first four days of menstruation
Study: 28357598
Drug: Superficial dentin
Normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Superficial dentin groups (all treatments)
Study: 23803136
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 mg initial dose, followed by 75 mg/day for 90 days) plus aspirin (75 mg/day for 21 days)
Study: 23803136
Drug: Aspirin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (75 mg/day for 90 days)
Study: 23803136
Drug: Clopidogrel-aspirin group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel-aspirin group
Study: 21693699
Drug: Ezetimibe/simvastatin 10
Normalized name: Ezetimibe/Simvastatin 10 MG-10 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe/simvastatin 10 mg/20 mg in the morning (within 1 hour of breakfast)
Study: 21693699
Drug: Ezetimibe/simvastatin 10
Normalized name: Ezetimibe/Simvastatin 10 MG-10 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe/simvastatin 10 mg/20 mg in the evening (within 1 hour of dinner)
Study: 18300746
Drug: Glucose-insulin-potassium (GIK)
Normalized name: glucose / potassium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-insulin-potassium (GIK) treatment
Study: 16608780
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TA) 0.75 g loading dose before surgery and 250 mg/h during surgery (total 1.5 g)
Study: 16608780
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TA) and Saline solution (control)
Study: 14600575
Drug: Intermittent interleukin-2
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent interleukin-2 (IL-2) therapy
Study: 12847572
Drug: Doxazosin standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin standard formulation
Study: 8782296
Drug: Kurume solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kurume solution with 1% albumin (group 2)
Study: 8782296
Drug: GIK solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIK solution with 1% albumin (group 4)
Study: 8782296
Drug: Kurume solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kurume solution without albumin (group 1)
Study: 8782296
Drug: GIK solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIK solution without albumin (group 3)
Study: 6148872
Drug: Nadolol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol (mean dosage, 87 +/- 43 mg/day)
Study: 27093774
Drug: Skilled operator
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Skilled operator using one-step self-etch (G-Bond)
Study: 27093774
Drug: Unexperienced operators
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unexperienced operators using one-step self-etch (G-Bond)
Study: 12368364
Drug: Spironolactone (12.5-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (12.5-50 mg/day)
Study: 7862911
Drug: Milacemide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milacemide (400 mg)
Study: 322921
Drug: Carbidopa (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbidopa (100 mg/day for 6 weeks)
Study: 24704626
Drug: Fenofibric acid
Normalized name: Fenofibric Acid
DrugBank: Fenofibric acid (DB13873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibric acid (FA) therapy alone
Study: 24704626
Drug: Fenofibric acid
Normalized name: Fenofibric Acid
DrugBank: Fenofibric acid (DB13873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibric acid (FA) and statin therapy
Study: 24704626
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy alone
Study: 18418975
Drug: Egb761 (Ginkgo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Egb761 (Ginkgo biloba extract) with chemotherapy (4 cycles of PA protocol)
Study: 16192262
Drug: Diet enriched
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet enriched with probiotics (6 x 10^9 CFU of Streptococcus thermophilus, Bifidobacterium lactis, Lactobacillus acidophilus) and 10 mg of zinc/day
Study: 12814810
Drug: Yasmin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yasmin (30 microg ethinylestradiol and 3 mg drospirenone)
Study: 1731027
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy with bacteriologic efficacy of 100%
Study: 1731027
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy with bacteriologic efficacy of 27% (consistent with no antibacterial therapy)
Study: 1731027
Drug: Tympanocentesis and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tympanocentesis and culture before and during therapy
Study: 1731027
Drug: Tympanocentesis before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tympanocentesis before therapy and assessment of clinical efficacy
Study: 22994106
Drug: Intravenous mexidol
Normalized name: Brexidol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous mexidol (300 mg daily for 2 weeks)
Study: 22994106
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment of primary open-angle glaucoma
Study: 20038730
Drug: Platinum-doublet chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-doublet chemotherapy for three cycles followed by gefitinib 250 mg orally once daily, until disease progression (arm B)
Study: 20038730
Drug: Platinum-doublet chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-doublet chemotherapy up to six cycles (arm A)
Study: 20038730
Drug: Platinum-doublet chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-doublet chemotherapy for three cycles followed by gefitinib 250 mg orally once daily (arm B)
Study: 17572319
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2% (500 mg in 48 hours via elastomeric pump)
Study: 17572319
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (250 mL as placebo)
Study: 16175565
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for SAD (exact intervention details not specified)
Study: 16175565
Drug: Nonresponders to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonresponders to treatment
Study: 2884856
Drug: Doxazosin 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin 12 mg (range 1 to 16)
Study: 2884856
Drug: Atenolol 91.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 91.8 mg (range 50 to 100)
Study: 18156639
Drug: 17beta‐estradiol for
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17beta‐estradiol for replacement therapy
Study: 12218723
Drug: EMTDS 0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMTDS 0.025 mg/day
Study: 12218723
Drug: EMTDS 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMTDS 0.05 mg/day
Study: 12218723
Drug: EMTDS 0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMTDS 0.075 mg/day
Study: 9468457
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II infusion (2 ng Ang II/kg per min)
Study: 8194508
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg elemental zinc (as zinc sulphate) for 7 days
Study: 8194508
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg elemental zinc (as zinc sulphate) for 7 days
Study: 11171824
Drug: Duodenal lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duodenal lipid infusion (L-2)
Study: 11171824
Drug: CCK-A antagonist
Normalized name: CCK-8
DrugBank: Sincalide (DB09142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CCK-A antagonist dexloxiglumide (5 mg/kg/h)
Study: 30249507
Drug: Ustekinumab (260
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab (260 mg for patients weighing 35-55 kg, 390 mg for patients weighing >55 kg and ≤85 kg, and 520 mg for patients weighing >85 kg) followed by subcutaneous injections of 90 mg every 8 weeks.
Study: 30249507
Drug: Placebo intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intravenous infusion at week 0 followed by subcutaneous injections every 8 weeks.
Study: 25407020
Drug: Same-day opioid
Normalized name: SAMe
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same-day opioid substitution treatment (methadone)
Study: 25407020
Drug: Regular health
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular health evaluation paired with low-barrier access to treatment
Study: 18035193
Drug: Risedronate 5
Normalized name: risedronate 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 5 mg PO QD for 24 months
Study: 16303729
Drug: Benazepril alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril alone (higher dose)
Study: 16303729
Drug: Losartan alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan alone (higher dose)
Study: 7629898
Drug: Oral buffered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral buffered deferoxamine solution (5 mg/kg elemental iron)
Study: 7629898
Drug: Control phase
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control phase (5 mg/kg elemental iron alone)
Study: 779516
Drug: Maltose treatment
Normalized name: Maltose
DrugBank: Maltose (DB03323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltose treatment (drinks sweetened with maltose 2 hours before operation)
Study: 30879908
Drug: Warmed intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warmed intravenous fluid group
Study: 25925033
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (3mg/kg infused over 1h)
Study: 19629674
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (leuprolide acetate 0.15 mg)
Study: 16984503
Drug: MMX mesalazine
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MMX mesalazine 1.2 g/day
Study: 31470599
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of non-animal chondroitin sulfate daily for 12 weeks
Study: 20921313
Drug: Raltegravir with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir with antacid
Study: 31925185
Drug: Genetically predicted
Normalized name: Burosumab (genetical recombination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetically predicted insulin (per pmol/L higher insulin)
Study: 28449232
Drug: 0.35 mg
Normalized name: nicotine 0.35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.35 mg GSK2881078 (in women)
Study: 28449232
Drug: 0.05 mg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg, 0.2 mg, 0.08 mg, 0.24 mg, 0.48 mg, 0.75 mg GSK2881078 (in men)
Study: 20017932
Drug: ACEI (Quinapril)
Normalized name: Veneno de Abeja Aceite de Vibora
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI (Quinapril) or Statins (Atorvastatin) or combination therapy
Study: 15152893
Drug: Montelukast (CysLTs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (CysLTs type‐1 receptor antagonist)
Study: 11700185
Drug: Granular formulation
Normalized name: Saxifraga granulata whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granular formulation of the insect growth regulator pyriproxyfen at a target dose of 0.01 mg a.i./litre
Study: 11700185
Drug: Granular formulation
Normalized name: Saxifraga granulata whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granular formulation of the insect growth regulator pyriproxyfen
Study: 8197772
Drug: Continuous hyperthermic
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous hyperthermic peritoneal perfusion (CHPP) with cisplatin (CDDP) 300 mg/kg and mitomycin C (MMC) 30 mg/kg
Study: 8197772
Drug: Continuous normothermic
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous normothermic peritoneal perfusion (CNPP) with cisplatin (CDDP) 300 mg/kg and mitomycin C (MMC) 30 mg/kg
Study: 2839628
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg twice daily (n = 16)
Study: 2839628
Drug: Hydrochlorothiazide 25
Normalized name: hydrochlorothiazide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 25 mg twice daily (n = 15)
Study: 2839628
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (10 mg enalapril and 25 mg hydrochlorothiazide twice daily, n = 6)
Study: 2839628
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy after 8 additional weeks
Study: 2839628
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy after one year
Study: 4937034
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 10% lignocaine
Study: 31780025
Drug: Curcumin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (500 mg/d)
Study: 19019444
Drug: Initial medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial medicine
Study: 7944835
Drug: Active antihypertensive
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active antihypertensive drug therapy (12.5 to 25 mg of chlorthalidone for step 1; 25 to 50 mg of atenolol for step 2; or 0.05 to 0.10 mg of reserpine if atenolol was contraindicated)
Study: 3065740
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose continuous chlorambucil (regimen A)
Study: 30352838
Drug: Fenretinide 200
Normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenretinide 200 mg daily
Study: 30352838
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Tamoxifen and Fenretinide
Study: 12173362
Drug: Erythromycin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (200 mg intravenously) during normoglycemia
Study: 12173362
Drug: Erythromycin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (200 mg intravenously) during hyperglycemia
Study: 10592403
Drug: Liquor carbonis
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liquor carbonis detergens (tar preparation)
Study: 1656738
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg once on day 1 followed by 250 mg once daily for 4 days
Study: 1656738
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V 250 mg every 6 hours for 10 days
Study: 27067478
Drug: Riociguat (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riociguat (2.5 mg three times per day)
Study: 25240461
Drug: ω‐3 PUFAs-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω‐3 PUFAs-containing fish oil (average DHA and EPA doses of 72.9 and 117.1 mg/kg b.w./day) for 12 months
Study: 23133592
Drug: Choline intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline intake of 480 mg/day
Study: 23133592
Drug: Choline intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline intake of 930 mg/day
Study: 8556698
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone and insulin-like growth factor 1 treatment
Study: 29056418
Drug: Dexmedetomidine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (25 μg kg−1)
Study: 29056418
Drug: Dexmedetomidine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (25 μg kg−1) with MK‐467 (600 μg kg−1)
Study: 26037292
Drug: Ticagrelor 180
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 180 mg loading dose before PCI
Study: 26037292
Drug: Prasugrel 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 60 mg loading dose at the time of PCI
Study: 15365929
Drug: 0.5% bupivacaine/1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine/1.5 microg/kg of fentanyl with 5 microg/mL of epinephrine (group IPBF)
Study: 15365929
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine with 5 microg/mL of epinephrine (group IPB)
Study: 15365929
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (group IVF)
Study: 25885964
Drug: LISA (less
Approvals — FDA: no, EMA: no, PMDA: no
Description: LISA (less invasive surfactant administration) group, n=47
Study: 24497658
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Insomnia and Pain (CBT-PI)
Study: 21098740
Drug: Bortezomib-dexamethasone induction
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib-dexamethasone induction therapy
Study: 19179299
Drug: Valsartan (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (oral suspension, 2 mg/kg, max 80 mg)
Study: 11351143
Drug: Pantoprazole 20
Normalized name: pantoprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 20 mg o.a.d.
Study: 26973167
Drug: Cortisol administration
Normalized name: cortisol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol administration 40 min before extinction memory retrieval
Study: 26973167
Drug: Placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administration 40 min before extinction memory retrieval
Study: 20844543
Drug: Efonidipine-based regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efonidipine-based regimen in strict-treatment group (target systolic BP <140 mm Hg)
Study: 20844543
Drug: Efonidipine-based regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efonidipine-based regimen in mild-treatment group (target systolic BP 140 to <160 mm Hg)
Study: 20844543
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with baseline eGFR <60 ml min⁻¹ per 1.73 m²
Study: 20844543
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with baseline eGFR ≥60 ml min⁻¹ per 1.73 m²
Study: 17715031
Drug: Esmolol (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (loading dose of 0.5 mg/kg in 30 ml normal saline over 5 min followed by an infusion of 50 microg.kg(‐1).min(‐1) until the end of surgery)
Study: 16042670
Drug: Erythromycin 1200
Normalized name: ERYTHROMYCIN 1200 mg in 30 g TOPICAL GEL [Spotex]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 1200 mg day(‐1) for 7 days
Study: 1761737
Drug: Cefpodoxime proxetil
Normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefpodoxime proxetil single doses of 100, 200, 400, 600, and 800 mg
Study: 1761737
Drug: Cefpodoxime proxetil
Normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefpodoxime proxetil multiple doses of 100, 200, and 400 mg twice daily for 15 days
Study: 1761737
Drug: Cefpodoxime proxetil
Normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefpodoxime proxetil (both single and multiple doses)
Study: 12364422
Drug: Raloxifene hydrochloride
Normalized name: Raloxifene Hydrochloride
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Raloxifene hydrochloride at 60 mg/d (group A)
Study: 12364422
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 tablet/d; group B)
Study: 9868651
Drug: 1 mg/(kg.d)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/(kg.d) liposomal amphotericin B (L‐AmB‐1)
Study: 9868651
Drug: 4 mg/(kg.d)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/(kg.d) liposomal amphotericin B (L‐AmB‐4)
Study: 3293408
Drug: Hygienic informational
Normalized name: INFORMATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hygienic informational therapy